Myosin loss in denervated rat soleus muscle after dexamethasone treatment

Hideo Horinouchi1, Toshihide Kumamoto, Noriyuki Kimura

  • 1Division of Neurology and Neuromuscular Disorders, Department of Brain and Nerve Science, Oita University Faculty of Medicine, Oita, Japan. horinouc@oita-med.ac.jp

Insights

Critical illness myopathy involves myosin loss, potentially due to altered myosin transcription and increased ubiquitin ligases. This study investigates the mechanisms behind myosin filament loss in critical illness myopathy.

Area of Science:

  • Muscle physiology
  • Cellular biology
  • Pathology

Background:

  • Critical illness myopathy (CIM) is characterized by acute muscle wasting.
  • A key pathological feature of CIM is the selective loss of thick myosin filaments.
  • CIM is associated with critical illness and exposure to corticosteroids and neuromuscular blocking agents.

Purpose of the Study:

  • To investigate the pathomechanism of myosin loss in critical illness myopathy.
  • To clarify the expression of myosin heavy chain (MHC) and ubiquitin ligase atrogin-1 in CIM.
  • To understand the role of the ubiquitin-proteasome pathway in CIM-related muscle wasting.

Main Methods:

  • Histological, immunohistochemical, SDS-PAGE, and RT-PCR analyses were performed on rat soleus muscles.
  • Experiments involved saline and dexamethasone treatments on both innervated and denervated muscles.
  • Expression levels of MHC and atrogin-1 were assessed.

Main Results:

  • Dexamethasone treatment led to significant MHC loss in denervated rat muscles.
  • mRNA expression of the ubiquitin ligase atrogin-1 was markedly increased in denervated, dexamethasone-treated muscles.
  • mRNA levels of the myosin isoform MHC I were decreased in these muscles, indicating altered transcription.

Conclusions:

  • Selective myosin loss in CIM may result from altered myosin transcription rates.
  • Upregulation of multiple ubiquitin ligases likely contributes to myosin loss via the ubiquitin-proteasome pathway.
  • These findings provide insight into the molecular mechanisms underlying muscle wasting in critical illness.
Abstract